- Home
- CTMX vs BNR Comparison
CTMX vs BNR Comparison
Compare CTMX & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- BNR
- Stock Information
- Founded
- CTMX 2008
- BNR 2014
- Country
- CTMX United States
- BNR China
- Employees
- CTMX N/A
- BNR N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- BNR Medical Specialities
- Sector
- CTMX Health Care
- BNR Health Care
- Exchange
- CTMX Nasdaq
- BNR Nasdaq
- Market Cap
- CTMX 62.3M
- BNR 61.7M
- IPO Year
- CTMX 2015
- BNR 2020
- Fundamental
- Price
- CTMX $0.59
- BNR $5.45
- Analyst Decision
- CTMX Buy
- BNR
- Analyst Count
- CTMX 6
- BNR 0
- Target Price
- CTMX $5.77
- BNR N/A
- AVG Volume (30 Days)
- CTMX 3.5M
- BNR 5.0K
- Earning Date
- CTMX 03-06-2025
- BNR 03-27-2025
- Dividend Yield
- CTMX N/A
- BNR N/A
- EPS Growth
- CTMX N/A
- BNR N/A
- EPS
- CTMX 0.38
- BNR N/A
- Revenue
- CTMX $138,103,000.00
- BNR $72,832,704.00
- Revenue This Year
- CTMX N/A
- BNR $52.90
- Revenue Next Year
- CTMX N/A
- BNR $48.35
- P/E Ratio
- CTMX $1.55
- BNR N/A
- Revenue Growth
- CTMX 36.45
- BNR N/A
- 52 Week Low
- CTMX $0.56
- BNR $2.62
- 52 Week High
- CTMX $5.85
- BNR $8.99
- Technical
- Relative Strength Index (RSI)
- CTMX 30.34
- BNR 41.94
- Support Level
- CTMX $0.60
- BNR $4.90
- Resistance Level
- CTMX $0.78
- BNR $5.78
- Average True Range (ATR)
- CTMX 0.06
- BNR 0.44
- MACD
- CTMX -0.00
- BNR -0.10
- Stochastic Oscillator
- CTMX 13.69
- BNR 35.62
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.